Providing Answers, Support, and Hope in Texas
Conduit Pharmaceuticals Announces Phase 2a Clinical Trial of AZD1656 for Treating Multiple Autoimmune Diseases, Including Lupus
Conduit Pharmaceuticals announced they will be conducting a Phase 2a clinical trial to evaluate AZD1656 for the treatment of multiple autoimmune diseases, including systemic lupus erythematosus (SLE), lupus nephritis (LN), and ANCA-associated vasculitis.
AZD1656, is a HK-4 glucokinase activator which is an anti-diabetic drug designed to regulate blood sugars and enhance beta cell function in people with diabetes. While originally developed by AstraZeneca for diabetes treatment, this Phase2a, double-blind study will investigate the drug’s potential for expanded use into new therapeutic areas for those living with autoimmune diseases.
Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about treatments being studied for lupus.